All HCS Pharma should be listed on the Frankfurt stock exchange by the end of the year. Currently, the company will be launching an exclusive pre-IPO stock as tokens on the European Digital Assets Exchange | EDSX offering investors a 20% discount on the listed shares.
The company that owns a breakthrough technology to recreate in vitro organs is aiming at becoming a biotech leader in drug discovery, cell therapy, cosmetology and cultivated meat in 5 years’ time.
HCS Pharma is already a French biotech company with an independent company evaluation tapping into 200 mln euro. Lille, France is home to the BIOMIMESYS team. They create and market 3D cell culture products and in vitro models. These tools allow miniaturization and automation of high throughput screening. High throughput screening analyzes the effects of many products’ efficacy as well as toxicity. This is possible due to the disruptive BIOMIMESYS® technology. Thus, it offers unique products to customers in pharmaceuticals, cosmetics, and food.
BIOMIMESYS® is a groundbreaking 3D technology that enables the faithful reproduction of the microenvironment of any organ/tissue, healthy or cancerous. BIOMIMESYS is a sophisticated hydroscaffold. It uses hyaluronic acid as its base. The scaffold has a hybrid composition of hydrogel and solid materials. It also has defined bioactivities and tunable viscoelasticity. This allows it to reproduce the behaviors of normal and cancerous tissue microenvironments. It can study the wide range of mechanical conditions in tumors.
Together with its exclusive and patented BIOMIMESYS technology, HCS Pharma will revolutionize the entire biotechnology industry by discovering new treatments (drugs/cellular therapies) that are more effective against cancer, Alzheimer’s and Parkinson’s disease.
BIOMIMESYS will also be a major technology for developing cellular agriculture from animal cells and providing a new source of animal protein.
Thanks to its unique, exclusive and patented technology, HCS Pharma has received several awards and distinctions in Europe and Asia:
HCS Pharma has participated also into the Invest Horizon EU Commission programme during which coaching programs allowed the company to be challenged by investors, academics and ex-entrepreneurs and finally to be ranked in the top 50 deep tech EU excellent companies (https://investhorizon.eu/portfolio-companies).
HCS Pharma has set up a team of 10 scientists and technicians. They have over 77 years of combined experience in cell biology, biomaterials, and pharmaceuticals. The team is both competent and qualified for their scientific work. All have relevant expertise in all critical functions: R&D, in vitro modeling systems, automation and industrialization, production and quality.
The addition of three experts in international business development and three advised experts from the pharmaceutical industry have also reinforced the team.
R&D is supported by a committee of scientific experts. These experts come from academic research in several fields. Among fields are stem cells, microsystems, metabolic diseases, neurobiology, and oncology. Overall, they closely advise and guide the management teams of HCS Pharma in its R&D strategy.
Based in Zug, the platform is fully compliant with all Swiss laws related to financial intermediaries, banking, anti-money laundering, and organized trading facilities. Among its core values, there are innovative solutions through blockchain technology, which ensures security and liquidity.
EDSX is the first platform in Europe with primary and secondary markets for both institutional and retails. EDSX is a pioneering platform that employs the world’s leading technology to globally list security tokens in both primary and secondary markets, listing digital securities of real financial instruments to the public with a decentralized peer-to-peer exchange. Our goal is to fully engage every aspect of the financial revolution.
Do you have a question for us?
Send your query here: